Upgrade to Finviz Elite: Get our fastest platform speed, real-time data, and unlimited screening & charting. Start Free Trial

Last Close
Feb 06  •  04:00PM ET
28.86
Dollar change
+1.10
Percentage change
3.96
%
Feb 06, 7:35 AMTG Therapeutics announces new real-world and pediatric study data for BRIUMVI in multiple sclerosis being presented at the ACTRIMS annual forum and posted on its website today.
IndexRUT P/E10.39 EPS (ttm)2.78 Insider Own7.27% Shs Outstand155.21M Perf Week-1.94%
Market Cap4.58B Forward P/E18.60 EPS next Y1.55 Insider Trans-0.22% Shs Float147.21M Perf Month-4.88%
Enterprise Value4.70B PEG0.12 EPS next Q0.35 Inst Own64.16% Short Float18.54% Perf Quarter-15.22%
Income447.47M P/S8.61 EPS this Y1910.00% Inst Trans0.00% Short Ratio14.05 Perf Half Y3.48%
Sales531.90M P/B7.38 EPS next Y-48.55% ROA55.55% Short Interest27.29M Perf YTD-3.19%
Book/sh3.91 P/C34.82 EPS next 5Y149.15% ROE111.96% 52W High46.48 -37.91% Perf Year-12.99%
Cash/sh0.83 P/FCF- EPS past 3/5Y- - ROIC52.04% 52W Low25.28 14.16% Perf 3Y72.09%
Dividend Est.- EV/EBITDA45.66 Sales past 3/5Y266.39% 364.59% Gross Margin85.30% Volatility4.48% 5.03% Perf 5Y-40.46%
Dividend TTM- EV/Sales8.84 EPS Y/Y TTM3184.55% Oper. Margin19.32% ATR (14)1.27 Perf 10Y253.24%
Dividend Ex-Date- Quick Ratio2.89 Sales Y/Y TTM100.88% Profit Margin84.13% RSI (14)43.35 Recom1.56
Dividend Gr. 3/5Y- - Current Ratio3.82 EPS Q/Q9974.69% SMA20-3.17% Beta1.88 Target Price44.43
Payout0.00% Debt/Eq0.42 Sales Q/Q92.79% SMA50-5.34% Rel Volume0.81 Prev Close27.76
Employees338 LT Debt/Eq0.42 EarningsNov 03 BMO SMA200-13.69% Avg Volume1.94M Price28.86
IPODec 14, 1995 Option/ShortYes / Yes EPS/Sales Surpr.1010.10% 6.31% Trades Volume1,574,848 Change3.96%
Date Action Analyst Rating Change Price Target Change
Oct-06-25Resumed H.C. Wainwright Buy $60
Jul-10-25Resumed Goldman Neutral $37
Oct-29-24Initiated TD Cowen Buy $50
Aug-02-23Upgrade Goldman Sell → Neutral $16 → $12
Jun-26-23Resumed Jefferies Buy $55 → $40
May-20-22Initiated BofA Securities Underperform $5
Feb-23-22Reiterated B. Riley Securities Buy $49 → $35
Nov-15-21Downgrade Goldman Neutral → Sell $33 → $26
Apr-20-21Initiated Goldman Neutral $50
Apr-19-21Reiterated H.C. Wainwright Buy $79 → $89
Today 03:33AM
Feb-06-26 07:30AM
Jan-27-26 07:30AM
Jan-15-26 10:31AM
Jan-14-26 04:39PM
10:52AM Loading…
10:52AM
09:45AM
09:25AM
05:03AM
Jan-13-26 05:05PM
04:25PM
Jan-07-26 07:30AM
Dec-19-25 08:32AM
Nov-28-25 07:30AM
Nov-19-25 08:30AM
04:00PM Loading…
Nov-10-25 04:00PM
12:01PM
Nov-05-25 09:45AM
Nov-04-25 10:26AM
Nov-03-25 04:25PM
04:00PM
08:53AM
07:09AM
07:00AM
Oct-31-25 07:30AM
Oct-28-25 05:55PM
10:00AM
07:30AM
Oct-27-25 10:00AM
Sep-25-25 06:24AM
09:10AM Loading…
Sep-24-25 09:10AM
Sep-10-25 07:30AM
Sep-08-25 07:30AM
Sep-04-25 07:30AM
Sep-03-25 12:40PM
11:30AM
07:30AM
Aug-28-25 08:00AM
Aug-05-25 01:06PM
12:12PM
09:30AM
03:00AM
Aug-04-25 01:14PM
11:29AM
08:10AM
07:04AM
07:00AM
Jul-30-25 10:00AM
07:30AM
Jul-29-25 10:24AM
10:00AM
Jul-17-25 02:05PM
Jul-15-25 01:08PM
Jul-10-25 02:24PM
Jul-02-25 12:05PM
Jun-30-25 09:22PM
Jun-16-25 09:47AM
Jun-06-25 07:30AM
Jun-02-25 08:00AM
May-30-25 07:30AM
May-27-25 07:30AM
May-19-25 06:20AM
May-09-25 10:28AM
May-06-25 03:03AM
May-05-25 11:20PM
03:37PM
01:30PM
10:55AM
08:10AM
07:08AM
07:00AM
May-01-25 09:20AM
Apr-30-25 10:01AM
07:30AM
Apr-28-25 06:20AM
Apr-23-25 06:06PM
01:59AM
Apr-16-25 11:32AM
Apr-10-25 11:50AM
07:30AM
Apr-08-25 07:30AM
Apr-07-25 03:08PM
08:00AM
07:30AM
Apr-03-25 05:00AM
Apr-02-25 04:35PM
Mar-28-25 09:44AM
Mar-21-25 03:22PM
Mar-19-25 04:16PM
Mar-17-25 05:33AM
Mar-14-25 10:36AM
Mar-11-25 09:49AM
Mar-08-25 12:05PM
Mar-07-25 05:23PM
07:30AM
Mar-06-25 12:22PM
Mar-04-25 05:09AM
02:01AM
12:42AM
Mar-03-25 05:08PM
TG Therapeutics, Inc. engages in the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its product pipeline includes TG-1501, TG-1701, Ublituximab, and Umbralisib. The company was founded by Michael Sean Weiss and Laurence H. Shaw on May 18, 1993 and is headquartered in Morrisville, NC.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Echelard YannDirectorNov 24 '25Sale32.575,000162,850223,816Nov 25 05:31 PM
Echelard YannDirectorNov 24 '25Proposed Sale32.575,000162,850Nov 24 04:04 PM
Lonial SagarDirectorSep 11 '25Sale32.2420,852672,26894,061Sep 12 04:42 PM
Lonial SagarDirectorSep 11 '25Proposed Sale32.2420,852672,233Sep 11 04:55 PM
Echelard YannDirectorJun 13 '25Sale36.9410,000369,400228,816Jun 16 05:47 PM
Echelard YannDirectorJun 13 '25Proposed Sale36.9310,000369,348Jun 13 12:48 PM